We read with interest the article by Deshpande et al. 1 on bitter taste receptors (TAS2Rs) in the lungs and the expression of TAS2Rs on human airway smooth muscle (ASM). The authors describe experiments in which TAS2R agonists, such as chloroquine, evoked relaxation of mouse tracheal rings that was threefold greater in magnitude than that elicited by b-adrenergic receptor agonists 1 (the current gold-standard bronchodilator therapy for asthma and chronic obstructive pulmonary disease 2 ). We sought to investigate the uncharacteristically weak bronchodilator activity of isoproterenol in human tissue.
Deshpande et al. reply:
Belvisi et al. 1 show in human bronchi that the bitter taste receptor (TAS2R) agonist chloroquine evokes marked relaxation; this is in agreement with our findings in mouse airways 2 . They note, however, an equivalent efficacy (degree of maximal relaxation) with the b-agonist isoproterenol in human bronchi 1 . In our paper, we carried out the vast majority of intact airway physiology experiments in mice, in which we found that bitter tastants had a greater efficacy compared with isoproterenol 2 . We never stated that TAS2R agonists were more potent than b-agonists, and we note that the differences in the potency (the EC 50 ) of isoproterenol and chloroquine are comparable in our study 2 and that of Belvisi et al. 1 . In our paper, we specifically noted that the threefold greater efficacy of TAS2R agonists compared to the b-agonist isoproterenol referred to mouse airways 2 . With the limited number of human airways that we studied, we were not in a position to provide quantitative efficacy data in human airways. We have now examined additional a b c d
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